Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
January 14 2021 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a
biopharmaceutical company focused on discovering and developing
novel products for patients with cancer, today announced that
Steven Fruchtman, MD, President & CEO, will present a Company
overview at NobleCon17, Noble Capital Markets Seventeenth Annual
Small and Microcap Investor Conference being held virtually January
19th and 20th. The conference is virtual, with no cost,
obligation, or restrictions to attend: www.noblecon17.com.
Presentation Details
Date: Wednesday, January 20th at 4:30p EST (Track 1)
- 20-minute
presentation
- 20-minute live video
breakout / Q&A immediately following the scheduled
presentation
A high-definition video webcast of the
presentation will be available the following day on the Company’s
website (www.onconova.com), and as part of a complete catalog of
presentations to be rebroadcast on Channelchek
(www.channelchek.com) next month.
About Onconova Therapeutics,
Inc.
Onconova Therapeutics is a biopharmaceutical
company focused on discovering and developing novel products for
patients with cancer. The Company has proprietary targeted
anti-cancer agents designed to disrupt specific cellular pathways
that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase
inhibitor ON 123300 is currently in a dose-escalation and expansion
Phase 1 trial in China, and a dose-escalation and expansion Phase 1
trial is planned in the U.S. to commence in the first half of 2021.
Onconova’s product candidate oral rigosertib is currently in a
dose-escalation and expansion Phase 1 investigator-initiated study
targeting patients with KRAS+ lung adenocarcinoma in combination
with nivolumab. Preclinical work with rigosertib in COVID-19 is
ongoing as well. Although some preclinical experiments with
rigosertib in cellular models demonstrated marked inhibition of
SARS-CoV-2 replication, we do not anticipate conducting clinical
trials with rigosertib in COVID-19 without securing additional
funding. For more information, please visit www.onconova.com.
About Noble Capital Markets,
Inc.
Noble Capital Markets (“Noble”) is a
research-driven boutique investment bank that has supported small
& microcap companies since 1984. As a FINRA and SEC licensed
and registered broker-dealer, Noble provides institutional-quality
equity research, merchant and investment banking, wealth
management, and order execution services. In 2005, Noble
established NobleCon, an investor conference that has grown
substantially over the last decade+. In 2018 Noble launched
www.channelchek.com – an investment community dedicated exclusively
to small and micro-cap companies and their industries. Channelchek
is tailored to meet the needs of self-directed investors and
financial professionals and is the first service to offer
institutional-quality research to the public, for FREE at every
level without a subscription. More than 6,000 emerging growth
companies are listed on the site, with growing content including
webcasts, industry sector reports, advanced market data and
balanced news.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova’s expectations regarding the
registered direct offering, its patents and clinical development
plans including [patient enrollment timelines and] indications for
its product candidates. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should," "approximately" or other words
that convey uncertainty of future events or outcomes. Although
Onconova believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including the success and
timing of Onconova's clinical trials and regulatory agency and
institutional review board approvals of protocols, Onconova’s
ability to continue as a going concern, the need for additional
financing, Onconova’s collaborations, market conditions and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Contact information
Company Contact:Avi
OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
Investor Contact:LHA Investor
Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024